has sponsored live events, journal education, and internet-based CME activities and has awarded more than 80,000 hours of CME credit.Early View from The Oncologist
- Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors
- The European Medicines Agency Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
- Long‐Term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Updated Analysis With Up to 5 Years of Follow‐Up
- Remember Your Why… An Oncologist's Reflections on Running During the COVID‐19 Pandemic
- Redefining The Treatment Endpoints in Oncology
- Impact of Home Parenteral Nutrition on Quality of Life in Cancer Patients: Don't Throw the Baby Out With the Bath Water
- Supplemental Parenteral Nutrition in Patients with Cancer
- ED Visits for Emesis following Chemotherapy: Guideline Non‐adherence, OP‐35, and a Path Back to the Future
- Cabozantinib and Panitumumab for RAS Wild‐Type Metastatic Colorectal Cancer
- Reconsidering dexamethasone for anti‐emesis when combining chemotherapy and immunotherapy